CO5280154A1 - Anticuerpos y fragmento fv que reconocen el antigeno ior c2 - Google Patents
Anticuerpos y fragmento fv que reconocen el antigeno ior c2Info
- Publication number
- CO5280154A1 CO5280154A1 CO00087150A CO00087150A CO5280154A1 CO 5280154 A1 CO5280154 A1 CO 5280154A1 CO 00087150 A CO00087150 A CO 00087150A CO 00087150 A CO00087150 A CO 00087150A CO 5280154 A1 CO5280154 A1 CO 5280154A1
- Authority
- CO
- Colombia
- Prior art keywords
- ior
- antibodies
- antibody
- fragment
- recognizing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Anticuerpo recombinante y fragmento de tipo Fv de cadena sencilla derivados del anticuerpo monoclonal murino IOR C5 producido por el hibridoma con número de depósito ECCC 97061101, donde dicho anticuerpo recombinante contiene las Regiones Determinantes de la Complementariedad (CDRs) del anticuerpo IOR C5 y regiones constantes humanas en las cadenas pesadas y ligeras.Composición farmacéutica para el tratamiento de tumores malignos de colon y recto, sus metástasis y recidivas que contiene uno de los anticuerpos recombinantes de las reivindicaciones de la 1 a la 5, y un excipiente apropiado para su aplicación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1999196A CU22921A1 (es) | 1999-11-16 | 1999-11-16 | Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5280154A1 true CO5280154A1 (es) | 2003-05-30 |
Family
ID=5459527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00087150A CO5280154A1 (es) | 1999-11-16 | 2000-11-16 | Anticuerpos y fragmento fv que reconocen el antigeno ior c2 |
Country Status (16)
Country | Link |
---|---|
US (1) | US6891023B1 (es) |
EP (1) | EP1174441A2 (es) |
JP (1) | JP2003514831A (es) |
KR (1) | KR100827627B1 (es) |
CN (1) | CN1230446C (es) |
AR (1) | AR026463A1 (es) |
AU (1) | AU783622B2 (es) |
BR (1) | BR0007827A (es) |
CA (1) | CA2359577A1 (es) |
CO (1) | CO5280154A1 (es) |
CU (1) | CU22921A1 (es) |
EA (1) | EA005169B1 (es) |
MX (1) | MXPA01007261A (es) |
TW (1) | TWI233440B (es) |
WO (1) | WO2001036485A2 (es) |
ZA (1) | ZA200105803B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0228832D0 (en) * | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
CN101389760A (zh) * | 2006-02-28 | 2009-03-18 | 尼莫克斯股份有限公司 | 有效治疗肿瘤或其他需要除去或破坏细胞的病症的肽 |
JP5924624B2 (ja) * | 2011-04-28 | 2016-05-25 | 国立研究開発法人理化学研究所 | 生物材料を透明化する方法、及びその利用 |
CN103562702A (zh) | 2011-05-20 | 2014-02-05 | 独立行政法人理化学研究所 | 生物材料用透明化试剂、及其利用 |
EP3035026A4 (en) | 2013-08-14 | 2017-04-26 | Riken | Composition for preparing biomaterial with excellent light-transmitting property, and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
EP0885404B1 (en) | 1996-03-07 | 2001-05-02 | Agfa-Gevaert N.V. | Apparatus for the processing of photographic sheet material |
CU22640A1 (es) * | 1996-03-12 | 2000-12-22 | Centro Inmunologia Molecular | Composición farmacéutica y kit que contienen anticuerpos monoclonales para marcaje con isótopos radioactivos. sus usos para el diagnóstico y tratamiento de tumores colorrectales, sus metástasis y recidivas |
-
1999
- 1999-11-16 CU CU1999196A patent/CU22921A1/es unknown
-
2000
- 2000-11-14 AR ARP000105994A patent/AR026463A1/es active IP Right Grant
- 2000-11-16 JP JP2001538974A patent/JP2003514831A/ja active Pending
- 2000-11-16 KR KR1020017008965A patent/KR100827627B1/ko not_active IP Right Cessation
- 2000-11-16 EA EA200100782A patent/EA005169B1/ru not_active IP Right Cessation
- 2000-11-16 CN CNB008039542A patent/CN1230446C/zh not_active Expired - Fee Related
- 2000-11-16 US US09/889,480 patent/US6891023B1/en not_active Expired - Fee Related
- 2000-11-16 MX MXPA01007261A patent/MXPA01007261A/es active IP Right Grant
- 2000-11-16 WO PCT/CU2000/000004 patent/WO2001036485A2/es active Application Filing
- 2000-11-16 CA CA002359577A patent/CA2359577A1/en not_active Abandoned
- 2000-11-16 AU AU15130/01A patent/AU783622B2/en not_active Ceased
- 2000-11-16 CO CO00087150A patent/CO5280154A1/es active IP Right Grant
- 2000-11-16 EP EP00977398A patent/EP1174441A2/en not_active Ceased
- 2000-11-16 BR BR0007827-1A patent/BR0007827A/pt not_active Application Discontinuation
-
2001
- 2001-01-30 TW TW089126622A patent/TWI233440B/zh not_active IP Right Cessation
- 2001-07-13 ZA ZA200105803A patent/ZA200105803B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA200100782A1 (ru) | 2002-02-28 |
KR100827627B1 (ko) | 2008-05-07 |
US6891023B1 (en) | 2005-05-10 |
AR026463A1 (es) | 2003-02-12 |
CN1230446C (zh) | 2005-12-07 |
AU783622B2 (en) | 2005-11-17 |
AU1513001A (en) | 2001-05-30 |
EA005169B1 (ru) | 2004-12-30 |
EP1174441A2 (en) | 2002-01-23 |
BR0007827A (pt) | 2001-10-30 |
CA2359577A1 (en) | 2001-05-25 |
MXPA01007261A (es) | 2002-06-04 |
WO2001036485A2 (es) | 2001-05-25 |
WO2001036485A3 (es) | 2001-11-08 |
KR20020008113A (ko) | 2002-01-29 |
CN1344276A (zh) | 2002-04-10 |
JP2003514831A (ja) | 2003-04-22 |
CU22921A1 (es) | 2004-02-20 |
ZA200105803B (en) | 2003-01-06 |
TWI233440B (en) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2523810T3 (es) | Procedimiento para la producción de inmunoglobulinas humanizadas | |
AR044076A1 (es) | Anticuerpos recombinantes y fragmentos que reconocen el gangliosido n- glicolil gm3 y su uso para diagnostico y tratamiento de tumores | |
ATE454903T1 (de) | Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper | |
AR052065A1 (es) | Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos | |
PE20090046A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
PE20020972A1 (es) | Anticuerpos recombinantes asociados a gangliosidos | |
RS51829B (sr) | Ljudska antitela specifična za interleukin 15 (il-15) | |
CL2010000789A1 (es) | Anticuerpo monoclonal anti integrina alfabeta6, que inhibe la union de alfav-beta-6al peptido asociado a latencia (pal); composicion; uso para tratar fibrosis, psoriasis, cancer, daño agudo de pulmon o sindrome de alpont; uso para deteccion de alfa-vbetas; hibridoma con n° de acceso atcc pta-3646 (div.sol.no. 513-03) | |
RS52889B (sr) | Terapijsko humano anti-il-1r1 monoklonsko antitelo | |
UY29573A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
LT2005099A (en) | Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof | |
RU2008128471A (ru) | Биологические материалы и их применение | |
ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
CY1107708T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης | |
UY30524A1 (es) | Anticuerpos dirigidos a avb(beta)6 y sus usos | |
CY1112611T1 (el) | Ανθρωποποιημενα αντισωματα αντι-ngf | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
AR085874A2 (es) | Un anticuerpo monoclonal o un fragmento del mismo que se une a un antigeno | |
PT699237E (pt) | Fvs de cadeia anti-egfr e anticorpos anti-egfr | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
RS54624B1 (en) | MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3 | |
ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
ATE280835T1 (de) | Apoptose induzierender monoklonaler antikörper | |
ES2625823T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
CO5280154A1 (es) | Anticuerpos y fragmento fv que reconocen el antigeno ior c2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |